---
document_datetime: 2025-12-02 05:37:56
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/voxzogo.html
document_name: voxzogo.html
version: success
processing_time: 0.116712
conversion_datetime: 2025-12-28 08:22:11.35353
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Voxzogo

[RSS](/en/individual-human-medicine.xml/67473)

##### Authorised

This medicine is authorised for use in the European Union

vosoritide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Voxzogo](#news-on)
- [More information on Voxzogo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Voxzogo is a medicine for treating achondroplasia in patients aged 4 months and older whose bones are still growing.

Achondroplasia is an inherited disease caused by a mutation (change) in a gene called fibroblast growth-factor receptor 3 ( *FGFR3* ). The mutation affects growth of almost all bones in the body including the skull, spine, arms and legs, resulting in very short stature with a characteristic appearance.

Achondroplasia is rare, and Voxzogo was designated an 'orphan medicine' (a medicine used in rare diseases) on 24 January 2013. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/EU3121094](https://beta.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1094) .

Voxzogo contains the active substance vosoritide.

Expand section

Collapse section

## How is Voxzogo used?

The medicine can only be obtained with a prescription. Treatment with Voxzogo must be started and supervised by a doctor experienced in the treatment of growth disorders or abnormal growth of bones.

Voxzogo is given as an injection under the skin once a day, preferably around the same time of day. The site of injection should be changed with each injection. The recommended dose is calculated according to the patient's body weight.

Treatment should only be started when achondroplasia is confirmed by genetic testing and should end when the patient is not likely to grow any further.

Voxzogo injections can be given by the patients' caregiver once they have been trained appropriately.

For more information about using Voxzogo, see the package leaflet or contact your doctor or pharmacist.

## How does Voxzogo work?

In patients with achondroplasia, the *FGFR3* gene, which regulates growth, is permanently 'switched on'. This prevents normal growth of bones, leading to bones that are shorter than normal. The active substance in Voxzogo, vosoritide, works by binding to a receptor (target) called natriuretic peptide receptor type B (NPR-B), which reduces the activity of *FGFR3* . This stimulates growth of bones, thereby improving the symptoms of the disease.

## What benefits of Voxzogo have been shown in studies?

Voxzogo was more effective than placebo (dummy treatment) at increasing growth rate after 52 weeks of treatment in a study involving 121 children aged from 5 to 17 years with confirmed achondroplasia. Children who received Voxzogo grew about 1.57 cm more during the year of treatment than those who received placebo. In addition, the results suggest that the improvement in growth is maintained.

Voxzogo was more effective than placebo at increasing growth rate in a second study involving 75 children aged from 4 months to less than 5 years with confirmed achondroplasia. The main measure of effectiveness was change in height Z-score, a measure which compares the patient's height to the average expected for their age and gender. After one year of treatment, children given Voxzogo had on average a greater improvement in height Z-score than those given placebo. Children who received Voxzogo also grew about 0.8 cm more during the year of treatment than those who received placebo.

## What are the risks associated with Voxzogo?

For the full list of side effects and restrictions with Voxzogo, see the package leaflet.

The most common side effects with Voxzogo (which may affect more than 1 in 10 people) are injection site reactions (such as swelling, redness, itching or pain), vomiting and decreased blood pressure.

## Why is Voxzogo authorised in the EU?

Voxzogo is effective at increasing the growth rate in children with achondroplasia aged 4 months and older. This may increase final height, allowing persons with achondroplasia to perform daily activities more easily. The side effects of the medicine are considered manageable. The safety profile in children below 5 years of age is similar to that in older children. The European Medicines Agency decided that Voxzogo's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Voxzogo?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Voxzogo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Voxzogo are continuously monitored. Suspected side effects reported with Voxzogo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Voxzogo

Voxzogo received a marketing authorisation valid throughout the EU on 26 August 2021.

Voxzogo : EPAR - Medicine overview

Reference Number: EMA/473914/2023

English (EN) (111.52 KB - PDF)

**First published:** 09/09/2021

**Last updated:** 24/11/2023

[View](/en/documents/overview/voxzogo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-356)

български (BG) (137.65 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/bg/documents/overview/voxzogo-epar-medicine-overview_bg.pdf)

español (ES) (112.05 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/es/documents/overview/voxzogo-epar-medicine-overview_es.pdf)

čeština (CS) (133.13 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/cs/documents/overview/voxzogo-epar-medicine-overview_cs.pdf)

dansk (DA) (111.9 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/da/documents/overview/voxzogo-epar-medicine-overview_da.pdf)

Deutsch (DE) (114.64 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/de/documents/overview/voxzogo-epar-medicine-overview_de.pdf)

eesti keel (ET) (109.47 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/et/documents/overview/voxzogo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (145.1 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/el/documents/overview/voxzogo-epar-medicine-overview_el.pdf)

français (FR) (113.1 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/fr/documents/overview/voxzogo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (133.34 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/hr/documents/overview/voxzogo-epar-medicine-overview_hr.pdf)

italiano (IT) (111.26 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/it/documents/overview/voxzogo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (145.78 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/lv/documents/overview/voxzogo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (133.39 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/lt/documents/overview/voxzogo-epar-medicine-overview_lt.pdf)

magyar (HU) (134.02 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/hu/documents/overview/voxzogo-epar-medicine-overview_hu.pdf)

Malti (MT) (134.6 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/mt/documents/overview/voxzogo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (112.48 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/nl/documents/overview/voxzogo-epar-medicine-overview_nl.pdf)

polski (PL) (139.03 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/pl/documents/overview/voxzogo-epar-medicine-overview_pl.pdf)

português (PT) (112.22 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/pt/documents/overview/voxzogo-epar-medicine-overview_pt.pdf)

română (RO) (137.76 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/ro/documents/overview/voxzogo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (133.05 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/sk/documents/overview/voxzogo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (132.8 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/sl/documents/overview/voxzogo-epar-medicine-overview_sl.pdf)

Suomi (FI) (109.16 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/fi/documents/overview/voxzogo-epar-medicine-overview_fi.pdf)

svenska (SV) (109.76 KB - PDF)

**First published:**

09/09/2021

**Last updated:**

24/11/2023

[View](/sv/documents/overview/voxzogo-epar-medicine-overview_sv.pdf)

Voxzogo : EPAR - Risk management plan summary

English (EN) (102.96 KB - PDF)

**First published:** 09/09/2021

**Last updated:** 20/03/2025

[View](/en/documents/rmp-summary/voxzogo-epar-risk-management-plan-summary_en.pdf)

## Product information

Voxzogo : EPAR - Product information

English (EN) (1.13 MB - PDF)

**First published:** 09/09/2021

**Last updated:** 18/11/2025

[View](/en/documents/product-information/voxzogo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-497)

български (BG) (1.23 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/bg/documents/product-information/voxzogo-epar-product-information_bg.pdf)

español (ES) (1.1 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/es/documents/product-information/voxzogo-epar-product-information_es.pdf)

čeština (CS) (1.15 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/cs/documents/product-information/voxzogo-epar-product-information_cs.pdf)

dansk (DA) (1.11 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/da/documents/product-information/voxzogo-epar-product-information_da.pdf)

Deutsch (DE) (1.07 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/de/documents/product-information/voxzogo-epar-product-information_de.pdf)

eesti keel (ET) (1.36 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/et/documents/product-information/voxzogo-epar-product-information_et.pdf)

ελληνικά (EL) (1.3 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/el/documents/product-information/voxzogo-epar-product-information_el.pdf)

français (FR) (1.11 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/fr/documents/product-information/voxzogo-epar-product-information_fr.pdf)

hrvatski (HR) (1.12 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/hr/documents/product-information/voxzogo-epar-product-information_hr.pdf)

íslenska (IS) (1.1 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/is/documents/product-information/voxzogo-epar-product-information_is.pdf)

italiano (IT) (1.06 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/it/documents/product-information/voxzogo-epar-product-information_it.pdf)

latviešu valoda (LV) (1.37 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/lv/documents/product-information/voxzogo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.18 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/lt/documents/product-information/voxzogo-epar-product-information_lt.pdf)

magyar (HU) (1.2 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/hu/documents/product-information/voxzogo-epar-product-information_hu.pdf)

Malti (MT) (1.21 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/mt/documents/product-information/voxzogo-epar-product-information_mt.pdf)

Nederlands (NL) (1.06 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/nl/documents/product-information/voxzogo-epar-product-information_nl.pdf)

norsk (NO) (1.08 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/no/documents/product-information/voxzogo-epar-product-information_no.pdf)

polski (PL) (1.21 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/pl/documents/product-information/voxzogo-epar-product-information_pl.pdf)

português (PT) (1.16 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/pt/documents/product-information/voxzogo-epar-product-information_pt.pdf)

română (RO) (1.21 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/ro/documents/product-information/voxzogo-epar-product-information_ro.pdf)

slovenčina (SK) (1.18 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/sk/documents/product-information/voxzogo-epar-product-information_sk.pdf)

slovenščina (SL) (1.17 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/sl/documents/product-information/voxzogo-epar-product-information_sl.pdf)

Suomi (FI) (1.1 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/fi/documents/product-information/voxzogo-epar-product-information_fi.pdf)

svenska (SV) (1.1 MB - PDF)

**First published:**

09/09/2021

**Last updated:**

18/11/2025

[View](/sv/documents/product-information/voxzogo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000300615 17/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Voxzogo : EPAR - All authorised presentations

English (EN) (44.58 KB - PDF)

**First published:** 09/09/2021

[View](/en/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-173)

български (BG) (56.74 KB - PDF)

**First published:**

09/09/2021

[View](/bg/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_bg.pdf)

español (ES) (46.78 KB - PDF)

**First published:**

09/09/2021

[View](/es/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (64.89 KB - PDF)

**First published:**

09/09/2021

[View](/cs/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (48.71 KB - PDF)

**First published:**

09/09/2021

[View](/da/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (50.99 KB - PDF)

**First published:**

09/09/2021

[View](/de/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (46.86 KB - PDF)

**First published:**

09/09/2021

[View](/et/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (64.25 KB - PDF)

**First published:**

09/09/2021

[View](/el/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_el.pdf)

français (FR) (47.24 KB - PDF)

**First published:**

09/09/2021

[View](/fr/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (64.51 KB - PDF)

**First published:**

09/09/2021

[View](/hr/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (47.2 KB - PDF)

**First published:**

09/09/2021

[View](/is/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (45.82 KB - PDF)

**First published:**

09/09/2021

[View](/it/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (66.09 KB - PDF)

**First published:**

09/09/2021

[View](/lv/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (67.55 KB - PDF)

**First published:**

09/09/2021

[View](/lt/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (68.04 KB - PDF)

**First published:**

09/09/2021

[View](/hu/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (68.86 KB - PDF)

**First published:**

09/09/2021

[View](/mt/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (48.43 KB - PDF)

**First published:**

09/09/2021

[View](/nl/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (49.27 KB - PDF)

**First published:**

09/09/2021

[View](/no/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_no.pdf)

polski (PL) (70.18 KB - PDF)

**First published:**

09/09/2021

[View](/pl/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_pl.pdf)

português (PT) (49.1 KB - PDF)

**First published:**

09/09/2021

[View](/pt/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_pt.pdf)

română (RO) (64.35 KB - PDF)

**First published:**

09/09/2021

[View](/ro/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (66.51 KB - PDF)

**First published:**

09/09/2021

[View](/sk/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (56.18 KB - PDF)

**First published:**

09/09/2021

[View](/sl/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (45.61 KB - PDF)

**First published:**

09/09/2021

[View](/fi/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (48.71 KB - PDF)

**First published:**

09/09/2021

[View](/sv/documents/all-authorised-presentations/voxzogo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Voxzogo Active substance vosoritide International non-proprietary name (INN) or common name vosoritide Therapeutic area (MeSH) Achondroplasia Anatomical therapeutic chemical (ATC) code M05BX

### Pharmacotherapeutic group

Drugs for treatment of bone diseases

### Therapeutic indication

Voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

## Authorisation details

EMA product number EMEA/H/C/005475

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

BioMarin International Limited

Shanbally

Opinion adopted 24/06/2021 Marketing authorisation issued 26/08/2021 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Voxzogo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (138.11 KB - PDF)

**First published:** 27/05/2025

**Last updated:** 18/11/2025

[View](/en/documents/procedural-steps-after/voxzogo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Voxzogo : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (148.99 KB - PDF)

**First published:** 20/06/2023

**Last updated:** 17/07/2024

[View](/en/documents/procedural-steps-after/voxzogo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Voxzogo-H-C-PSUSA-00010952-202308: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/335501/2024

English (EN) (120.86 KB - PDF)

**First published:** 17/07/2024

[View](/en/documents/scientific-conclusion/voxzogo-h-c-psusa-00010952-202308-epar-scientific-conclusions-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Voxzogo-H-C-005475-II-0006 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/487942/2023

English (EN) (2.59 MB - PDF)

**First published:** 21/11/2023

[View](/en/documents/variation-report/voxzogo-h-c-005475-ii-0006-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Voxzogo (II-06)

Adopted

Reference Number: EMA/410364/2023

English (EN) (94.8 KB - PDF)

**First published:** 15/09/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-voxzogo-ii-06_en.pdf)

Voxzogo-H-C-005475-P46-007 : EPAR - Assessment report

Adopted

Reference Number: EMA/5898/2022

English (EN) (5.36 MB - PDF)

**First published:** 24/02/2022

[View](/en/documents/variation-report/voxzogo-h-c-005475-p46-007-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Voxzogo : Orphan maintenance assessment report (initial authorisation)

Reference Number: EMADOC-1700519818-700332

English (EN) (324.25 KB - PDF)

**First published:** 09/09/2021

[View](/en/documents/orphan-maintenance-report/voxzogo-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Voxzogo : EPAR - Public assessment report

Reference Number: EMA/397108/2021

English (EN) (4.05 MB - PDF)

**First published:** 09/09/2021

[View](/en/documents/assessment-report/voxzogo-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Voxzogo

Adopted

Reference Number: EMA/CHMP/337860/2021

English (EN) (141.94 KB - PDF)

**First published:** 25/06/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-voxzogo_en.pdf)

#### News on Voxzogo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023) 15/09/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-june-2021) 25/06/2021

[New treatment for people with dwarfism](/en/news/new-treatment-people-dwarfism) 25/06/2021

#### More information on Voxzogo

- [EU/3/12/1094 - orphan designation for treatment of achondroplasia](/en/medicines/human/orphan-designations/eu-3-12-1094)
- [EMEA-002033-PIP01-16-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002033-pip01-16-m03)
- [Voxzogo - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/voxzogo)
- [EMEA-002033-PIP02-23 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002033-pip02-23)
- [A multicentre, non-interventional study to evaluate long-term safety in patients with achondroplasia treated with Voxzogo® (vosoritide) (BMN 111-603) - post-authorisation study](https://catalogues.ema.europa.eu/study/50251)

**This page was last updated on** 18/11/2025

## Share this page

[Back to top](#main-content)